Development of Anti-e after Platelet Concentrate TransfusionSohaib Abu-Farsakh, Renee Bowen, Neil Blumberg and Majed A. Refaai*
Department of Pathology and Laboratory Medicine, University of Rochester Medicine, Rochester, NY, USA
- *Corresponding Author:
- Majed Refaai, MD
University of Rochester, 601 Elmwood Avenue
Box-608, Rochester, NY 14642, USA
Tel: 585 276-3927
E-mail: [email protected]
Received date: August 07, 2015 Accepted date: September 09, 2015 Published date: September 14, 2015
Citation: Abu-Farsakh S, Bowen R, Blumberg N, Refaai MA (2015) Development of Anti-e after Platelet Concentrate Transfusion. J Blood Disord Transfus 6:308. doi:10.4172/2155-9864.1000308
Copyright: © 2015 Abu-Farsakh S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Platelet concentrates (PC) is prepared from donated whole blood units by centrifugation and subsequent pooling of 4-6 units Advancing Transfusion and Cellular Therapies Worldwide Advancing Transfusion and Cellular Therapies Worldwide. Thus, PC may contain a small amount of donor RBC. We report a case of a 60 year-old male patient with past medical history of coronary artery disease, who presented to our emergency department with shortness of breath. Previous medical history indicated a recent admission, one month prior, to another local hospital for shock and respiratory failure. Type and screen (T/S) done at that time reveal an O+ blood type with negative antibody screen. During that admission, the patient received only 5 doses of PC (2-group O+, 2-group O-, and 1-group A-). He denied any other recent blood product transfusions at any other facility. Our current T/S, and before any transfusions, showed a positive antibody screen. A panel for antibody identification was performed. The antibody reacted with 9 out of 10 reagent cells. The reactivity was predominately at room temperature and 37°C phases indicating an IgM class antibody. Some reactivity was also seen at AHG (anti-human globulin) phase indicating an IgG class antibody. The auto control was negative. Testing additional cells revealed an anti-e specificity. Patient’s “e” antigen typing was performed and found to be negative indicating that this is a true allo-antibody. Since anti-e antibody predominantly exists as an IgG immunoglobulin class antibody, the presence of IgM class reactivity suggests that this may be a newly developed antibody. This case illustrates that antibodies to RBC antigens can develop after platelet transfusion.